BioCentury | May 6, 2020
Management Tracks

Mendel named GenMark’s CEO; plus SutroVax, Illumina, Arrowhead, Tessa and more

...Inc., which was acquired by Endo International plc (NASDAQ:ENDP) for $2.6 billion. Protein engineering company Codexis Inc....
...England Ltd. Robin Sawka, BioCentury Staff GenMark Diagnostics Inc. SutroVax Inc. Illumina Inc. Arrowhead Pharmaceuticals Inc. Tessa Therapeutics Pte. Ltd. Impel NeuroPharma Inc. Codexis Inc. Imara...
BioCentury | Dec 6, 2019
Preclinical News

Dec. 5 Preclinical Quick Takes: Simpler synthesis of Merck’s HIV therapy; plus MRSA antibiotic, once-monthly oral contraceptive

...Codexis design efficient synthesis of Phase II HIV therapy Merck & Co. Inc. (NYSE:MRK) and Codexis Inc....
...three-step biocatalytic cascade in a single aqueous solution using nine enzymes -- five engineered using Codexis’...
...overall yield using the new process, described in a Science report , was 51%, and Codexis...
BioCentury | Jun 21, 2019
Financial News

June 20 Financial Quick Takes: Zymeworks raises $175M; plus Casdin, Scholar Rock and more

...it proposed the offering after market hours. Casdin invests $50M in Codexis Synthetic biology company Codexis Inc....
...challenge. Its U.S. counterpart kicked off in May. Elizabeth S. Eaton, Staff Writer Axial Biotherapeutics Inc. Casdin Capital LLC Codexis Inc. Cybrexa...
BioCentury | Apr 8, 2019
Company News

Management tracks: WuXi AppTec, Kymab, Acceleron

...of Compugen Ltd. (NASDAQ:CGEN; Tel Aviv:CGEN) and Realm Therapeutics plc (LSE:RLM; NASDAQ:RLM). Protein engineering company Codexis Inc....
...Jim Lalonde will resign as SVP of R&D to pursue other opportunities, effective May 31. Codexis...
BioCentury | Feb 25, 2019
Company News

Management tracks: Viriom, Matinas, Atreca

...technology officer. Fish was SVP of healthcare technology strategy firm Fletcher Spaght. Protein engineering company Codexis Inc....
BioCentury | Dec 1, 2017
Company News

Codexis, Nestle deal

...Codexis Inc. (NASDAQ:CDXS) to license exclusive worldwide rights to CDX-6114, an oral enzyme, to treat phenylketonuria. Codexis...
...pipeline or may discover in the next five years. Furthermore, Nestle and Codexis will use Codexis'...
...business areas. Codexis Inc. (NASDAQ:CDXS), Redwood City, Calif. Nestle S.A. (SIX:NESN), Vevey, Switzerland Business: Encocrine/Metabolic Elizabeth S. Eaton Codexis Inc. Nestle...
BioCentury | Jul 7, 2017
Finance

Generalists needed

...NASDAQ:CYTX) 4/11/17 $9.5 $35.5 $35.7 1% Catalyst Biosciences Inc. (NASDAQ:CBIO) 4/7/17 $20.7 $13.6 $19.8 46% Codexis Inc....
BioCentury | Apr 7, 2017
Financial News

Codexis completes follow-on

...Protein engineering company Codexis Inc. (NASDAQ:CDXS) raised $22 million on April 7 through the sale of 5.5...
...$4 in a follow-on underwritten by Jefferies and Craig-Hallum Capital. Codexis Inc. (NASDAQ:CDXS), Redwood City, Calif. Alicia Parker Codexis Inc....
BioCentury | Sep 28, 2015
Company News

Codexis deal

...Codexis said a proof-of-concept study is expected to be completed in about six months. If Codexis’...
...elects to continue the program, “enzyme evolution” is expected to last six to 12 months. Codexis...
...expects to generate R&D service revenues from the deal. Codexis declined to provide further details. Codexis Inc....
BioCentury | Sep 7, 2015
Company News

Codexis Inc, Merck deal

...to use Codexis’ CodeEvolver technology to develop custom-designed enzymes for use in manufacturing Merck therapeutics. Codexis...
...million in technology transfer milestones, which is expected to occur in the next two years. Codexis...
...technology to determine which gene and enzyme mutations are beneficial or detrimental to manufacturing processes. Codexis...
Items per page:
1 - 10 of 100
BioCentury | May 6, 2020
Management Tracks

Mendel named GenMark’s CEO; plus SutroVax, Illumina, Arrowhead, Tessa and more

...Inc., which was acquired by Endo International plc (NASDAQ:ENDP) for $2.6 billion. Protein engineering company Codexis Inc....
...England Ltd. Robin Sawka, BioCentury Staff GenMark Diagnostics Inc. SutroVax Inc. Illumina Inc. Arrowhead Pharmaceuticals Inc. Tessa Therapeutics Pte. Ltd. Impel NeuroPharma Inc. Codexis Inc. Imara...
BioCentury | Dec 6, 2019
Preclinical News

Dec. 5 Preclinical Quick Takes: Simpler synthesis of Merck’s HIV therapy; plus MRSA antibiotic, once-monthly oral contraceptive

...Codexis design efficient synthesis of Phase II HIV therapy Merck & Co. Inc. (NYSE:MRK) and Codexis Inc....
...three-step biocatalytic cascade in a single aqueous solution using nine enzymes -- five engineered using Codexis’...
...overall yield using the new process, described in a Science report , was 51%, and Codexis...
BioCentury | Jun 21, 2019
Financial News

June 20 Financial Quick Takes: Zymeworks raises $175M; plus Casdin, Scholar Rock and more

...it proposed the offering after market hours. Casdin invests $50M in Codexis Synthetic biology company Codexis Inc....
...challenge. Its U.S. counterpart kicked off in May. Elizabeth S. Eaton, Staff Writer Axial Biotherapeutics Inc. Casdin Capital LLC Codexis Inc. Cybrexa...
BioCentury | Apr 8, 2019
Company News

Management tracks: WuXi AppTec, Kymab, Acceleron

...of Compugen Ltd. (NASDAQ:CGEN; Tel Aviv:CGEN) and Realm Therapeutics plc (LSE:RLM; NASDAQ:RLM). Protein engineering company Codexis Inc....
...Jim Lalonde will resign as SVP of R&D to pursue other opportunities, effective May 31. Codexis...
BioCentury | Feb 25, 2019
Company News

Management tracks: Viriom, Matinas, Atreca

...technology officer. Fish was SVP of healthcare technology strategy firm Fletcher Spaght. Protein engineering company Codexis Inc....
BioCentury | Dec 1, 2017
Company News

Codexis, Nestle deal

...Codexis Inc. (NASDAQ:CDXS) to license exclusive worldwide rights to CDX-6114, an oral enzyme, to treat phenylketonuria. Codexis...
...pipeline or may discover in the next five years. Furthermore, Nestle and Codexis will use Codexis'...
...business areas. Codexis Inc. (NASDAQ:CDXS), Redwood City, Calif. Nestle S.A. (SIX:NESN), Vevey, Switzerland Business: Encocrine/Metabolic Elizabeth S. Eaton Codexis Inc. Nestle...
BioCentury | Jul 7, 2017
Finance

Generalists needed

...NASDAQ:CYTX) 4/11/17 $9.5 $35.5 $35.7 1% Catalyst Biosciences Inc. (NASDAQ:CBIO) 4/7/17 $20.7 $13.6 $19.8 46% Codexis Inc....
BioCentury | Apr 7, 2017
Financial News

Codexis completes follow-on

...Protein engineering company Codexis Inc. (NASDAQ:CDXS) raised $22 million on April 7 through the sale of 5.5...
...$4 in a follow-on underwritten by Jefferies and Craig-Hallum Capital. Codexis Inc. (NASDAQ:CDXS), Redwood City, Calif. Alicia Parker Codexis Inc....
BioCentury | Sep 28, 2015
Company News

Codexis deal

...Codexis said a proof-of-concept study is expected to be completed in about six months. If Codexis’...
...elects to continue the program, “enzyme evolution” is expected to last six to 12 months. Codexis...
...expects to generate R&D service revenues from the deal. Codexis declined to provide further details. Codexis Inc....
BioCentury | Sep 7, 2015
Company News

Codexis Inc, Merck deal

...to use Codexis’ CodeEvolver technology to develop custom-designed enzymes for use in manufacturing Merck therapeutics. Codexis...
...million in technology transfer milestones, which is expected to occur in the next two years. Codexis...
...technology to determine which gene and enzyme mutations are beneficial or detrimental to manufacturing processes. Codexis...
Items per page:
1 - 10 of 100